{
    "root": "d46a2b80-6fff-4b79-a86a-d8b02b5d746a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TYSABRI",
    "value": "20250321",
    "ingredients": [
        {
            "name": "natalizumab",
            "code": "3JB47N2Q2P"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "sodium phosphate, monobasic, monohydrate",
            "code": "593YOG76RN"
        },
        {
            "name": "sodium phosphate, dibasic, heptahydrate",
            "code": "70WT22SF4B"
        },
        {
            "name": "polysorbate 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "tysabri integrin receptor antagonist indicated treatment : multiple sclerosis ( multiple sclerosis ) tysabri indicated monotherapy treatment relapsing forms multiple sclerosis , include clinically isolated syndrome , relapsing-remitting disease , active secondary progressive disease , adults . tysabri increases risk pml [ ( 5.1 ) ] . initiating continuing treatment tysabri , physicians consider whether expected benefit tysabri sufficient offset risk . ( 1.1 ) crohn 's disease ( cd ) tysabri indicated inducing maintaining response remission adult patients moderately severely active crohn 's disease evidence inflammation inadequate response , unable tolerate , conventional cd therapies inhibitors tnf-α . ( 1.2 ) important limitations : cd , tysabri used combination immunosuppressants inhibitors tnf-α . ( 1.2 )",
    "contraindications": "300 mg infused intravenously one hour , every four weeks . give intravenous push bolus ( 2.1 , 2.2 ) tysabri solution must administered within 48 hours preparation ( 2.3 ) observe patients infusions . post-infusion , first 12 infusions , observe patients one hour infusion complete . patients received 12 infusions without evidence hypersensitivity reaction , observe patients post-infusion 13th subsequent infusions according judgment . ( 2.4 ) cd , discontinue patients experienced therapeutic benefit 12 weeks induction therapy , patients discontinue chronic concomitant steroids within six months starting therapy ( 2.2 )",
    "warningsAndPrecautions": "tysabri ( natalizumab ) injection , sterile , preservative-free , colorless clear slightly opalescent solution dilution prior intravenous infusion , supplied one 300 mg/15 ml ( 20 mg/ml ) single-dose vial per carton ( ndc 64406-008-01 ) . tysabri available registered infusion centers participating touch® prescribing program . locate infusion centers , contact biogen 1-800-456-2255. tysabri single-dose vials must refrigerated 2°c 8°c ( 36°f 46°f ) . beyond expiration date stamped carton vial label . shake freeze . protect light . store diluted tysabri solution refrigerated 2°c 8°c ( 36°f 46°f ) [ ( 2.3 ) ]",
    "adverseReactions": "tysabri contraindicated patients progressive multifocal leukoencephalopathy ( pml ) [ ( 5.1 ) ] . tysabri contraindicated patients hypersensitivity reaction tysabri . observed range urticaria anaphylaxis [ ( 5.5 ) ] .",
    "indications_original": "TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 )",
    "contraindications_original": "300 mg infused intravenously over one hour, every four weeks.  Do not give as an intravenous push or bolus ( 2.1 , 2.2 ) TYSABRI solution must be administered within 48 hours of preparation ( 2.3 ) Observe patients during all infusions. Post-infusion, for the first 12 infusions, observe patients for one hour after the infusion is complete. For patients who have received 12 infusions without evidence of a hypersensitivity reaction, observe patients post-infusion for the 13th and subsequent infusions according to clinical judgment. ( 2.4 ) In CD, discontinue in patients that have not experienced therapeutic benefit by 12 weeks of induction therapy, and in patients that cannot discontinue chronic concomitant steroids within six months of starting therapy ( 2.2 )",
    "warningsAndPrecautions_original": "TYSABRI (natalizumab) injection, a sterile, preservative-free, colorless and clear to slightly opalescent solution for dilution prior to intravenous infusion, is supplied as one 300 mg/15 mL (20 mg/mL) single-dose vial per carton (NDC 64406-008-01).\n\n                  TYSABRI is available only through registered infusion centers participating in the TOUCH® Prescribing Program. To locate these infusion centers, contact Biogen at 1-800-456-2255.\n\n                  TYSABRI single-dose vials must be refrigerated between 2°C to 8°C (36°F to 46°F). Do not use beyond the expiration date stamped on the carton and vial label. DO NOT SHAKE OR FREEZE. Protect from light. \n\n                  Store diluted TYSABRI solution refrigerated at 2°C to 8°C (36°F to 46°F) [see Dosage and Administration (2.3)]",
    "adverseReactions_original": "TYSABRI is contraindicated in patients who have or have had progressive multifocal leukoencephalopathy (PML) [see Warnings and Precautions (5.1)].\n\n                     TYSABRI is contraindicated in patients who have had a hypersensitivity reaction to TYSABRI. Observed reactions range from urticaria to anaphylaxis [see Warnings and Precautions (5.5)]."
}